Major Depressive Disorder Clinical Trials

365 recruitingLast updated: June 18, 2026

There are 365 actively recruiting major depressive disorder clinical trials across 58 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 4, Phase 1, Early Phase 1. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Toronto, Ontario, Canada. Updated daily from ClinicalTrials.gov.


Major Depressive Disorder Trials at a Glance

365 actively recruiting trials for major depressive disorder are listed on ClinicalTrialsFinder across 6 cities in 58 countries. The largest study group is Not Applicable with 184 trials, with the heaviest enrollment activity in New York, Boston, and Toronto. Lead sponsors running major depressive disorder studies include Centre for Addiction and Mental Health, Massachusetts General Hospital, and Unity Health Toronto.

Browse major depressive disorder trials by phase

Treatments under study

About Major Depressive Disorder Clinical Trials

Looking for clinical trials for Major Depressive Disorder? There are currently 264 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Major Depressive Disorder trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Major Depressive Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 365 trials

Recruiting
Not Applicable

Defining Neurobiological Links Between Substance Use and Mental Illness

Substance Use DisorderNormal PhysiologyMajor Depressive Disorder
National Institute on Drug Abuse (NIDA)620 enrolled1 locationNCT05538910
Recruiting
Phase 4

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

SchizophreniaMajor Depressive DisorderBipolar Disorder+2 more
Neurocrine Biosciences50 enrolled22 locationsNCT07105111
Recruiting
Not Applicable

Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice

Major Depressive Disorder (MDD)
National Science and Technology Council, Taiwan120 enrolled1 locationNCT07462013
Recruiting
Phase 1

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

DepressionHealthy VolunteerMajor Depressive Disorder
National Institute of Mental Health (NIMH)150 enrolled1 locationNCT03065335
Recruiting
Phase 1

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

DepressionMajor Depressive DisorderMajor Depression
National Institute of Mental Health (NIMH)70 enrolled1 locationNCT03973268
Recruiting
Phase 2

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Mild Neurocognitive DisorderMajor Depressive DisorderHIV
National Institute of Allergy and Infectious Diseases (NIAID)186 enrolled41 locationsNCT06705478
Recruiting
Not Applicable

RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS

DepressionSuicidal IdeationMajor Depressive Disorder
Medical University of South Carolina120 enrolled1 locationNCT05977439
Recruiting
Not Applicable

Magnesium Bisglycinate in Major Depressive Disorder

Major Depressive Disorder
All India Institute of Medical Sciences, Bhubaneswar84 enrolled1 locationNCT07633080
Recruiting
Not Applicable

Accelerated Treatment of Depressive Patients With tDCS

Major Depressive Disorder
University of Regensburg30 enrolled1 locationNCT07444242
Recruiting
Phase 2

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Major Depressive Disorder
AbbVie195 enrolled33 locationsNCT07276997
Recruiting
Phase 2

Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression

Major Depressive Disorder (MDD)Probiotic Intervention
First Affiliated Hospital of Chongqing Medical University60 enrolled2 locationsNCT07539805
Recruiting
Not Applicable

DBS for TRD With the Medtronic Percept PC

Major Depressive DisorderTreatment Resistant Depression
Helen Mayberg, MD10 enrolled1 locationNCT05773755
Recruiting
Phase 3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

DepressionDepression - Major Depressive DisorderDepression in Adults+3 more
Cybin IRL Limited330 enrolled67 locationsNCT06793397
Recruiting
Phase 4

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Major Depressive Disorder
Nova Scotia Health Authority400 enrolled10 locationsNCT05017311
Recruiting
Phase 2

Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression

Major Depressive Disorder (MDD)Probiotic Intervention
First Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT07645157
Recruiting
Phase 2

Mindfulness-based Psilocybin Therapy for PTSD

Depression - Major Depressive DisorderPost Traumatic Stress Disorder
Anthony P King30 enrolled1 locationNCT07104916
Recruiting
Not Applicable

Enhancing Slow Wave Sleep in Depression

Depression - Major Depressive Disorder
Wake Forest University Health Sciences12 enrolled1 locationNCT07143838
Recruiting
Not Applicable

Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients

Depression - Major Depressive DisorderChronic PainFibromyalgia
Hospital Ambroise Paré Paris36 enrolled1 locationNCT07642882
Recruiting
Not Applicable

tDCS: Sleep to Mood in Depression (S2M-D)

DepressionMajor Depressive DisorderMajor Depressive Episode+1 more
NYU Langone Health35 enrolled1 locationNCT07572526
Recruiting
Phase 2

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.153 enrolled21 locationsNCT07284667